By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Achillion Pharmaceuticals, Inc. 

300 George Street

New Haven  Connecticut  06511  U.S.A.
Phone: 203-624-7000 Fax: 203-624-7003


SEARCH JOBS


Industry
Pharmaceutical

Segment
Drug Discovery





Company News
USPTO Grants Composition Of Matter Patent To Achillion (ACHN) For Small Molecule Complement Alternative Pathway Factor D Inhibitors 3/22/2017 8:41:04 AM
Achillion (ACHN) Reports 2016 Fourth Quarter And Year-End Financial Results 2/24/2017 7:55:34 AM
IDBS E-WorkBook For Chemistry Enables Achillion (ACHN) To Go Paperless 2/8/2017 8:22:02 AM
Moving From Big Pharma To Biotech—A Conversation With Achillion (ACHN)'s CSO 2/1/2017 6:01:31 AM
Achillion (ACHN) Scores $15 Million Clinical Milestone From Janssen R&D for the Advancement of JNJ-4178 in Phase 2B 12/28/2016 7:44:56 AM
Achillion (ACHN) Release: Data Presented At American Society of Hematology Meeting Demonstrate Potential Advantages Of Factor D Inhibition For The Treatment Of Complement Alternative Pathway-Mediated Diseases 12/6/2016 8:02:03 AM
Achillion (ACHN) Announces Initiation Of Patient Dosing By Janssen Pharmaceutical In A Global, Short Treatment-Duration Phase 2b Study Of JNJ-4178 In Chronic HCV 11/30/2016 7:58:23 AM
Achillion (ACHN) Reports Third Quarter 2016 Financial Results And Provides Update On Clinical Programs 11/3/2016 8:57:19 AM
Achillion (ACHN) Announces 100% SVR12 In The 6-Week And 8-Week Cohorts In Janssen’s Phase II Trial Evaluating The Triple Combination Treatment Regimen Including Odalasvir, AL-335, And Simeprevir For Genotype 1 Treatment-Naïve HCV 9/26/2016 7:30:19 AM
Achillion (ACHN), Johnson & Johnson (JNJ)'s Hep C Candidate Scores a 100% Cure Rate in Phase IIa Trial 9/9/2016 5:46:17 AM
12345678910...
//-->